Tarsus Uses Veterinary Drug To Target Unserved Ocular Disease

With success on multiple endpoints in its first pivotal trial of lotilaner in Demodex blepharitis, Tarsus is working to bring the veterinary antiparasitic drug to market in multiple human indications.

Bobak Azamian, CEO, Tarsus Pharmaceuticals
Tarsus is driven by interest in nature, animal world, CEO Azamian says • Source: Tarsus Pharmaceuticals

Recently public company Tarsus Pharmaceuticals Inc. unveiled positive data from a Phase IIb/III study in eyelash mites on 21 June for an antiparasitic medicine initially developed to prevent tick and flea infestation in domestic animals such as dogs. In an interview, Tarsus CEO Bobak Azamian explained that there is precedent in both antiparasitic and ophthalmic medicine to adapt compounds initially developed for animal health uses.

The Irvine, CA-based firm, which raised more than $100m in its initial public offering in October, said TP-03, an ophthalmic...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Strategy

More from Business

  • How A New Healthcare Dialogue Is Driving Market Access In Mexico

    Companies stand a better chance of securing public reimbursement in Mexico for innovative medicines if they understand changing approaches to healthcare. The shift means the emergence of managed entry agreements and a focus on economic impact, explains AMIIF, Mexico's research-based pharmaceutical industry association.

  • How Novartis Is Elevating CVD Outcomes, Driving ‘Personalized Access’ In APMA

    Novartis’s APMA chief outlines the company’s tailored approach to deliver long-term outcomes, novel access solutions via innovative financing options and shape the CVD disease ecosystem in the extraordinarily diverse region. Partnering to build AI infrastructure is another key prong.

  • India Rare Diseases: Court Shows Path For Policy Action, Funding, Price Issues-- Test-2

    A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.